GLENMARK PHARMACEUTICALS LTD.

History

Year	Detail
1977	Glenmark was established as a generic drug and active pharmaceutical ingredient manufacturer by Emeritus Late Mr. Gracias Saldanha.
1979	Glenmark entered into the dermatology market with the launch of Candid Cream.
2001	The company forayed into manufacturing APIs and commenced operations at the Kurkumbh API manufacturing facility in Maharashtra, India.
2005	Glenmark launched front-end commercial sales in the U.S. To support its U.S. operations with high-quality products.
2006	Glenmark entered into an out-licensing deal of $31 million with Merck KGaA for its molecule Melogliptin.
2010	Glenmark entered an out-licensing deal with Sanofi-Aventis for its GRC 15300 molecule, a first-in-class TRPV3 antagonist. Glenmark received an upfront payment of $25 million.
2011	Glenmark out-licensed its first novel biological entity, GBR 500, to Sanofi-Aventis and received an upfront payment of $50 million and a milestone payment of $5 million.
2014	The company commissioned a new manufacturing facility in North Carolina, U.S., to develop injectable and oral solid dosages.
2015	Glenmark announced the strategic development & licensing agreement with Celon, Poland, for generic Seretide Accuhaler in Europe.
2016	Glenmark launched Ezetimibe, the first and only generic version of Zetia for treating high cholesterol in the U.S.
2022	Glenmark Specialty S.A. (Switzerland) received NDA approval from the U.S. Food and Drug Administration (FDA) for Ryaltris Nasal Spray, which is used to treat symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older.
2024	Glenmark collaborated with Ichnos to accelerate the search for a cure for cancer with their alliance, Ichnos Glenmark Innovation. This alliance will integrate the drug innovation capabilities of both companies to develop advanced therapies for the treatment of hematological malignancies and solid tumors.